“A lot of insurance payers interpreted this to mean that in order to get covered for the treatment, you also needed to start a new oral antidepressant.” Those requirements can make it more difficult ...

Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression ... as reflected in numerous patient experiences. For instance, one patient described emerging ...

“Spravato ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

“Spravato is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days, without the need for daily oral ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

We are a REMS certified Spravato Treatment Center. For over 25 years, I've cared for people of all ages impacted by traumatic life experiences. I strive to meet mental and behavioral health needs ...